Scinai Immunotherapeutics (SCNI) Cost of Revenue (2024 - 2026)

Scinai Immunotherapeutics has reported Cost of Revenue for 3 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 348.88% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (changed N/A YoY) and the FY2025 annual result came in at $6.7 million, up 443.05% from the prior year.
• Cost of Revenue fell to $1.6 million in Q1 2026 per SCNI's latest filing, from $1.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $1.7 million in Q2 2025 and troughed at $358000.0 in Q1 2025.
• A 3-year average of $888000.0 and a median of $417000.0 in 2024 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 348.88% in 2026, down 348.88% in 2026.
• Over 3 years, Cost of Revenue stood at $373000.0 in 2024, then soared by 351.74% to $1.7 million in 2025, then retreated by 4.63% to $1.6 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1.6 million, $1.7 million, and $358000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.